15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering ProKidney Corp, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $12.00 to $12.00, so the covering firms are broadly aligned. The average target of $12.00 sits 677% above the current $1.54. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.58 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Moderate Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to ProKidney Corp.
As of Jul, 1 of 1 firms rate PROK a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PROK EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.17 – $-0.12 · 5 analysts · +18% YoY
Next period, 5 analysts expect ProKidney Corp. to earn $-0.14 a share (range $-0.17 – $-0.12), versus $-0.12 a year earlier. Full-year consensus is $-0.54, growing to $-0.58 the year after.
REVENUE · NEXT QUARTER
$125.8K
Range $0 – $230.0K · 5 analysts · -42% YoY
Revenue is expected to reach $125.8K (range $0 – $230.0K), -42.0% year-over-year. Full-year consensus is $511.1K, rising to $449.8K next year.
Top analysts covering ProKidney Corp.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PROK.
#1
Anupam Rama
JP Morgan · Rank #62
Hold
No targeton PROK
Overall win rate
46%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #131
Buy
$10.00+547.2% to target
Overall win rate
43%
+ Follow
#3
Jason Gerberry
B of A Securities · Rank #136
Sell
$1.00-35.3% to target
Overall win rate
46%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #266
Buy
$12.00+676.7% to target
Overall win rate
32%
+ Follow
#5
Vamil Divan
Guggenheim
Buy
$7.00+353.1% to target
Coverage
—
+ Follow
PROK stock forecast FAQ
What is PROK's average 12-month price target?+
The 1 analysts with a live target average $12.00 for ProKidney Corp. over the next 12 months, ranging from a $12.00 high to a $12.00 low.
Is PROK stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover PROK?+
1 analysts have an active rating on ProKidney Corp., and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering PROK?+
Among analysts who currently cover PROK, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Hold.
What is ProKidney Corp.'s projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.17 – $-0.12) across 5 analysts. Full-year EPS is projected at $-0.54, rising to $-0.58 the following year.
How much revenue is ProKidney Corp. expected to report next quarter?+
Consensus revenue is $125.8K (range $0 – $230.0K). Full-year revenue is projected at $511.1K, growing to $449.8K next year.
Have analysts been upgrading or downgrading PROK lately?+
As of Jul, 1 of 1 firms rate PROK a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PROK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
